Liver fibrosis is characterized by an increased deposition of extracellular matrix constituents, resulting from an enhanced de novo synthesis of matrix proteins (fibrogenesis) and their compromised removal by matrix degrading enzymes (fibrolysis). The major cell type responsible for hepatic fibrogenesis is the activated hepatic stellate cell (HSC) 1 (1) (2) (3) (4) (5) . Therefore, this cell type is an important target for antifibrotic therapies. However, contrary to in vitro data, in vivo studies indicate that most antifibrogenic agents are not efficiently taken up by HSC. To attain HSC-specific uptake, drugs can be coupled to carrier molecules that are designed for selective uptake by target cells. To date, drug carriers to hepatocytes, Kupffer, and liver sinusoidal endothelial cells have been described extensively (6 -8) . Recently, we reported about a neoglycoprotein, albumin modified with mannose 6-phosphate moieties (M6P 28 -HSA), which preferentially distributed to HSC in fibrotic rat livers (9) . We now choose a different approach for the development of drug carriers. This approach is based on the use of peptide moieties as a homing device. These (cyclic) peptides are designed to recognize specific (pathological) receptors on target cells. If successful, this may have implications for the design of other receptor-specific carriers.
Specific interactions between cells and extracellular matrix components are mediated by transmembrane proteins, in particular the heterodimeric integrins. Cell-matrix interactions guide or modulate many cellular activities, such as adhesion, migration, differentiation, proliferation, and apoptosis (10 -12) . Many integrins recognize and bind the amino acid sequence Arg-Gly-Asp (RGD) present in various matrix proteins. Collagen type VI is a major matrix protein involved in the adhesion of cells to the surrounding matrix. In addition, it interacts with a number of other matrix molecules such as collagens type I and III, decorin, and hyaluronic acid (12) . The main cellular sources of collagen type VI in normal and fibrotic livers are HSC (13) . In normal livers, collagen type VI is localized in the portal areas and at the plasma membranes of hepatocytes, endothelial cells, and HSC within the lobule. The hepatic deposition of this type of collagen is increased during liver fibrosis, in particular in the fibrous septa that invade the lobule (14, 15) . Serum levels of collagen type VI allowed the non-invasive differentiation of children with liver fibrosis from those without fibrosis approaching a 100% accuracy (16) . It could be demonstrated that the core fragment of collagen type VI has potent growth factor activities stimulating DNA synthesis of mesenchymal cells severalfold via activation of erk2 and tyrosine phosphorylation of several proteins (17, 18) . Binding of cells to collagen type VI by integrins is RGD-dependent. Although several RGD sequences are found in collagen type VI, Marcellino and McDevitt (19) showed that the cyclic peptide C*GRGDSPC* specifically inhibited the attachment of collagen type VI to cells, while the RGD-dependent binding of fibronectin to these cells was not inhibited. Furthermore, the linear analogue of this peptide failed to inhibit the cellular attachment of collagen type VI (19) , indicating that a non-integrin collagen type VI receptor was antagonized by this peptide. Therefore, we studied whether C*GRGDSPC*, which selectively interferes with collagen type VI-mediated cell adhesion, can be used as a homing device to target to HSC in fibrotic livers. In this study, we present evidence that human serum albumin (HSA) modified with this cyclic peptide binds to HSC in vivo and in vitro and is applicable as a drug carrier to this crucial cell type in liver fibrosis.
EXPERIMENTAL PROCEDURES

Synthesis and Characterization of pCVI-HSA
Reagents-The cyclic peptide C*GRGDSPC* was prepared by Ansynth Service BV (Roosendaal, The Netherlands). HSA was obtained from the Central Laboratory of Blood Transfusion Services (Amsterdam, The Netherlands) and consisted mainly of monomeric protein. All other reagents were of the highest purity grade available.
Synthesis-The cyclic octapeptide C*GRGDSPC* was covalently coupled to HSA as illustrated in Fig. 1 . First, a sulfhydryl group was introduced into the cyclic peptide. Therefore, C*GRGDSPC* was dissolved in dimethyl formamide and reacted with N-succinimidyl S-acetyl thioacetate (Pierce) for 2 h in the presence of diisopropylethylamine. Primary ⑀-NH 2 groups of lysine moieties in HSA were derivatized with maleimido-hexanoyl-N-hydroxysuccinimide ester in phosphate-buffered saline, pH 7.2. Subsequently, the cyclic peptide was added to HSA. The molar ratio peptide to HSA determined the degree of substitution. Hydroxylamine was added to remove the protecting acetate group from the sulfhydryl group of the cyclic peptide. The mixture was stirred for 2 h. The obtained product was purified with Sephadex G-25SF gel chromatography (Amersham Pharmacia Biotech), lyophilized, and stored at Ϫ20°C until use.
Characterization-The molecular weight of pCVI-HSA and HSA was determined by a 7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fast protein liquid chromatography analysis. The fast protein liquid chromatography system was equipped with a Superdex-200 column (Amersham Pharmacia Biotech) and an UV detector (280 nm). The proteins (0.2 mg) were eluted with phosphate-buffered saline at a flow rate of 0.4 ml/min.
The amount of ␣-helices and ␤-sheets in pCVI-HSA was determined by recording circular dichroism (CD) spectra in the 197-250 nm range with an circular dichroism spectrometer model 62A DS (AVIV Instruments, Lakewood, NY) (20) . The spectra were the average of 5 scans (1 nm band width, 1-nm step width, 1 s averaging time per point) recorded at constant temperature (20°C). The spectrum of pCVI-HSA (0.2 mg/ml phosphate-buffered saline) was compared with the spectra of native HSA and HSA treated with dithiothreitol (Sigma), which induces linearization of proteins by cleavage of disulfide bridges (21) .
Radiolabeling
pCVI-HSA and HSA were labeled with 125 I as described by Mather and Ward (22) to a specific activity of 2.5 ϫ 10 6 cpm/g for in vivo and in vitro studies. Before each experiment, protein bound radioactivity was measured after precipitation with 10% trichloroacetic acid. The preparations were dialyzed against phosphate-buffered saline if the solution contained of Ͼ5% free 125 I.
FIG. 1.
Covalent coupling of the cyclic peptide moiety Cys-Gly-Arg-GlyAsp-Ser-Pro-Cys (‫؍‬C*GRGDSPC*, in which C* denotes the cyclizing cysteine residues) to HSA. I, first, a sulfhydryl group is introduced to the cyclic peptide by reaction with succinimideacetyl thioacetate (SATA). II, the ⑀-NH 2 groups of lysine in HSA are derivatized with maleimide-hexanoyl-N-hydroxysuccinimide ester (MHS). III, subsequently, the cyclic peptide is coupled to HSA. In this latter reaction, hydroxyl amine is used to remove the protecting acetate group from the sulfhydryl group of the cyclic peptide.
Animal Model of Liver Fibrosis
Male Wistar rats (Ϯ250 g, obtained from Harlan, Zeist, The Netherlands) were housed in 12-h light/dark cycles at constant temperature and humidity and maintained on standard lab chow and tap water. The study as presented was approved by the Local Committee for Care and Use of Laboratory Animals and was performed according to strict governmental and international guidelines on animal experimentation.
To induce liver fibrosis, the rats were submitted to common bile duct ligation (BDL) under fluothane/O 2 anesthesia (23). Three weeks after bile duct ligation (BDL3), these fibrotic rats were used for in vivo experiments. Previous studies showed that the livers of these rats displayed all signs of fibrosis, that is abundant HSC proliferation and excessive matrix deposition (7) .
In Vivo Experiments
Organ Distribution Studies with Radioactivity Detection-Distribution studies were performed as described (9) . The distributions of 125 IpCVI-HSA and 125 I-HSA were assessed at 10, 30, or 180 min after intravenous injection of tracer doses in the penis vene in normal and BDL3 rats.
In Vivo Localization of pCVI-HSA with Immunohistochemical Techniques-Anesthetized normal and BDL3 rats received an intravenous dose of 10 mg/kg pCVI-HSA (via the penis vene). Ten minutes after administration, specimens of liver, spleen, lungs, kidneys, and muscles were frozen in isopentane (Ϫ80°C) for immunohistochemical analysis. Since technical problems hampered the preparation of bone cryostat sections, acetone fixed specimens of the hind leg bone were embedded in glycol methacrylate plastic after dehydration in an alcohol series according to standard procedures (24) .
Immunohistochemical Analysis
Acetone-fixed cryostat sections (4 m) of liver, spleen, lung, and kidneys were stained for the presence of pCVI-HSA with a rabbit polyclonal antibody directed against HSA (Cappel, Organon Teknika, Turnhout, Belgium) according to standard indirect immunoperoxidase methods using aminoethyl carbazole (25) . The polyclonal antibody displayed no cross-reactivity with rat serum albumin.
Double Immunostaining-To assess whether the modified albumins were taken up by HSC, Kupffer cells, or endothelial cells, the liver sections were double stained with HSA antibodies and a cell typespecific marker (9) . HSC were demonstrated with two mouse monoclonal primary antibodies directed against desmin (Cappel) and glial fibrillary acidic protein (Biogenex, San Ramon, CA). Kupffer cells and endothelial cells were detected with the monoclonal antibodies ED2 and HIS52, respectively (both Serotec, Oxford, United Kingdom). The sections stained for the modified albumin and the hepatic cell markers were quantitatively evaluated in a double-blind manner by two independent observers as described before (9) . The number of double positive cells was related to the total number of HSA-positive cells yielding a relative accumulation of pCVI-HSA by each cell type. The double staining techniques were also used to examine spleen, lung, and kidneys for the co-localization of pCVI-HSA with fibroblast markers (with antibodies against desmin, ␣-smooth muscle actin (Sigma), and vimentin (DAKO, Glostrup, Denmark)), or with the monocyte/macrophage marker ED1 (DAKO).
Immunohistochemical Analysis of Plastic Sections-The presence of pCVI-HSA in plastic embedded bone was studied by immunohistochemical staining of 0.1% trypsine-treated sections (2 m) and anti-HSA IgG (9, 24) . The staining in bone was detected after amplification of the signal with peroxidase-conjugated goat anti-rabbit IgG and rabbit antigoat IgG. Glycol methacrylate-plastic embedded liver samples containing HSA were prepared and treated similarly and served as positive controls.
In Vitro Experiments
Isolation of HSC-The livers of male Wistar rats (450 -550 g) were perfused with Gey's balanced salt solution (GBSS) containing collagenase P (Roche Molecular Biochemicals, Mannheim, Germany), Pronase (Merck, Darmstadt, Germany), and DNase (Roche Molecular Biochemicals). The HSC were separated from the other hepatic cells by densitygradient centrifugation and collected at the top of an 11% Nycodenz solution (Nyegaard, Oslo, Norway). The cells were then cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc., Paisley, Scotland) containing 10% fetal calf serum, 100 units/ml penicillin, and 100 g/ml streptomycin (26). After 2 days, cell debris and nonadherent cells were removed by washing and the medium was changed every 2 or 3 days thereafter. Cells cultured for 2 days after isolation represented quiescent HSC, whereas those cultured for 10 days after isolation represented activated HSC (26) .
Binding I-HSA per dish in 0.2% bovine serum albumin/DMEM for 0.5 to 24 h at 4 and 37°C. The medium was removed after the incubation period and analyzed for the presence of degradation products by precipitation of the protein bound radioactivity with a 10% trichloroacetic acid solution. Subsequently, the dishes were washed three times with cold GBSS, and the cells were harvested with a cell scraper (Costar, Cambridge, MA) to assess the total amount of cell bound radioactivity.
We performed inhibition experiments to determine the specificity of binding and uptake of 125 I-pCVI-HSA to HSC. We added an excess of unlabeled pCVI-HSA (30 M dissolved in GBSS) to the incubation media at 4°C. At 37°C, 2 M monensin (Sigma, dissolved in ethanol), an inhibitor of endocytosis, was added to the incubation media.
Immunohistochemical Analysis-HSC (10 days old) were seeded on glass Lab-tek chamber slides (Nalge Nunc International, Naperville, IL) and recultured overnight in cDMEM. Adherent cells were incubated with 1 mg/ml pCVI-HSA or HSA for 2 h at 37°C. Subsequently, the wells were washed three times with DMEM and fixed with acetone/ methanol (1:1, v/v). To detect modified albumins bound to activated HSC, the slides were stained with anti-HSA antibodies as described above. Incubations of cells and pCVI-HSA were also performed in the presence of 1 g/ml soluble collagen type VI (18) or the polyanion suramin (200 M, obtained from ICN Biomedicals, Aurora, OH).
Slice Experiments-To determine the degradation of pCVI-HSA and HSA, we used precision-cut liver slices, containing all hepatic cells in their native state. Fresh slices (Ϯ12 mg wet weight) were prepared from BDL rat livers with a Krumdieck slicer and stored in ice-cold UW until the start of the experiments (27, 28) . The slices were incubated with 125 I-pCVI-HSA or 125 I-HSA (150,000 cpm/well), as described (9), for 2-24 h at 37°C. After the incubation period, the medium was used for the determination of released degradation products by precipitation of the protein bound radioactivity with 10% trichloroacetic acid.
Adhesion of pCVI-HSA to Matrix Proteins-To assess the binding of pCVI-HSA to matrix proteins, we coated 0.15 mg of collagen S (ϭ90% collagen type I, 10% collagen type III, and others, obtained from Roche Molecular Biochemicals) overnight at 37°C in 35-mm dishes. In addition, the individual matrix proteins collagen type I, III, IV, and VI (10 g/dish, collagen type I, III, and IV were obtained from Sigma) were coated to dishes. These dishes were washed twice with ice-cold GBSS, blocked with 1% bovine serum albumin/DMEM for 15 min at 4°C, and subsequently incubated with 50,000 cpm of 125 I-pCVI-HSA or 125 I-HSA/ dish in 0.2% bovine serum albumin/DMEM for 2 h at 4°C. After the incubation period, the dishes were washed three times with cold GBSS and the total amount of collagen bound radioactivity was harvested with a cell scraper (Costar) and measured with a ␥-counter.
Statistical Analysis-Results were expressed as the mean Ϯ S.D. Statistical analysis of the data was performed with an unpaired Student's t test. The differences were considered significant at p Ͻ 0.05.
RESULTS
Characterization of pCVI-HSA-After modification of albumin with the cyclic peptide C*GRGDSPC*, the molecular weight of the pCVI-HSA complex was demonstrated to be higher than that of unmodified HSA (Fig. 2A) . The molecular weight of one cyclic peptide moiety was 92,000. From the increase in molecular weight, we estimated that pCVI-HSA contained an average of 10 cyclic peptide moieties per HSA molecule. Only monomeric protein was detected after Coomassie Brilliant Blue staining of the gel, while no residual unmodified HSA was found in the pCVI-HSA preparation. In addition, fast protein liquid chromatography-Superdex analysis was performed with pCVI-HSA and HSA. The chromatograms of pCVI-HSA and HSA were similar as depicted in Fig. 2B , indicating minor polymerization of the protein after the chemical proce-dures. The major part of the pCVI-HSA preparation consisted of monomeric protein (75%). The decrease in the retention time from 34.5 min (HSA) to 33.0 min (pCVI-HSA) reflects the increased molecular weight of the modified albumin.
Attachment of cyclic peptide moieties to albumin might induce conformational changes in the HSA molecule. Therefore, we assessed the secondary structure of pCVI-HSA using circular dichroism analysis and compared the obtained spectrum to that of HSA. The CD spectra of both pCVI-HSA and HSA were alike (Fig. 3) , which indicates that the amount of ␣-helices and ␤-sheets are comparable in pCVI-HSA and HSA. HSA treated with dithiothreitol served as a positive control. The cleavage of disulfide bridges by this reducing agent resulted in unfolding of HSA and destruction of its secondary structure, which was reflected by a change in the CD spectrum (Fig. 3) .
Organ Distribution Studies of pCVI-HSA-The organ distribution of 125 I-pCVI-HSA was studied in normal rats and in rats with advanced liver fibrosis (BDL3). After intravenous administration of 125 I-pCVI-HSA, this drug carrier was rapidly cleared from the blood (Fig. 4, A and B) . Already at 10 min after injection, only 15 Ϯ 4% (normal rats) and 17 Ϯ 4% (BDL3 rats) of the pCVI-HSA dose was present in the blood. In contrast, the complete dose of 125 I-HSA was recovered in blood at that time point without significant distribution to any other organ (Fig.  4C) . No significant differences were found between the radioactivity detected in blood and in plasma indicating that pCVI-HSA did not bind to blood cells.
The organ responsible for most of the uptake of 125 I-pCVI-HSA was the liver. After 10 min 75 Ϯ 16 and 62 Ϯ 6% of the dose distributed to the livers of normal and BDL3 rats, respectively. The hepatic content of pCVI-HSA gradually declined with time and 125 I-pCVI-HSA and/or degradation products redistributed to urine, and to a minor degree to the intestinal tract, muscles, and skin. The radioactivity excreted by the kidneys into urine consisted of non-protein bound radioactivity as assessed after trichloroacetic acid precipitation. Minor amounts of the dose of 125 I-pCVI-HSA were taken up by the spleen (4.9 Ϯ 1.2 and 7.3 Ϯ 4.2% for normal and BDL3 rats, respectively) and kidneys (2.6 Ϯ 0.5 and 1.8 Ϯ 0.5% for normal and BDL3 rats, respectively). Also, radioactivity was recovered in bone, muscle, and skin of the rats. The accumulation of 125 I-pCVI-HSA in all organs and tissues was not significantly different between diseased and non-diseased rats at any time point tested.
Immunohistochemical analysis of organ sections confirmed the major distribution of pCVI-HSA to the liver in both normal and BDL3 rats. Also distribution to the spleen was detected immunohistochemically. The localization of pCVI-HSA in the spleen corresponded with vimentin staining, which outlined the venous sinusoids in the spleen. It did not correspond with desmin, ␣-smooth muscle actin, or ED1 (macrophage) staining. In BDL3 rats also, cells of the lung, identified as macrophages, stained positive for pCVI-HSA. In contrast to the staining found in the plastic-embedded livers, the staining in bone could only be detected after amplification of the peroxidase signal. The staining of bone was identified as nonspecific precipitated material in blood vessels and no cell associated staining was found. None of the other tissues stained positive for anti-HSA IgG at 10 min after administration of pCVI-HSA.
Intrahepatic Distribution of pCVI-HSA- Fig. 5A shows the localization of pCVI-HSA in BDL3 livers as detected immunohistochemically. In BDL3 as well as normal livers, the carrier pCVI-HSA distributed to the nonparenchymal cells, whereas no accumulation of this modified albumin could be found in hepatocytes or bile duct epithelial cells. pCVI-HSA did not bind to cells in the portal areas of BDL3 rat livers 10 min after intravenous injection. Double-staining of liver sections was performed to identify the cell type(s) responsible for hepatic accumulation of pCVI-HSA. In fibrotic rat livers, pCVI-HSA staining corresponded mainly with the localization of desmin and glial fibrillary acidic protein (Fig. 5B) , whereas in normal rat livers pCVI-HSA distributed predominantly to HIS52-positive endothelial cells.
Quantitative evaluation of the liver sections confirmed these observations (Table I ). In normal rat livers, 70 Ϯ 7% of total hepatic pCVI-HSA uptake was attributable to endothelial cells, whereas in BDL3 rat livers the major part of HSA positive cells (73 Ϯ 14%) were identified as HSC. This increase in HSC uptake in fibrotic livers was paralleled by a concomitantly decreased endothelial uptake (30 Ϯ 10%). Minor accumulation was found in Kupffer cells. Attempts to double label the transformed HSC (myofibroblasts) failed due to the insensitivity of the ␣-smooth muscle actin antibody with alkaline phosphatase detection, but lack of pCVI-HSA staining in the portal areas where actin-positive cells are most abundant indicates no uptake by the cells in these areas.
Binding and Internalization of pCVI-HSA by HSC in VitroCultured rat HSC were used to study the handling of pCVI-HSA by this cell type. First, we determined the binding and uptake of 125 I-pCVI-HSA to quiescent and activated HSC. The results were compared with data obtained by incubation of the cells with 125 I-HSA. As shown in Fig. 6 , significantly higher amounts of 125 I-pCVI-HSA bound to activated HSC at both 4 and 37°C as compared with 125 I-HSA. In contrast, quiescent HSC did not bind significant amounts of the modified albumin. Cell-associated radioactivity was significantly higher at 37°C than at 4°C, indicating cellular uptake of the protein. Since pCVI-HSA specifically bound to activated HSC, all other in vitro experiments were performed with activated cell cultures. To examine the specificity of the binding of pCVI-HSA to activated HSC, we incubated this modified albumin in the presence of excess unlabeled pCVI-HSA, which reduced the amount of 125 I-pCVI-HSA bound to HSC by 65% (p Ͻ 0.01, Fig.  8A ). To assess whether pCVI-HSA is taken up in HSC via receptor-mediated endocytosis, we incubated pCVI-HSA at 37°C in the presence of 2 M monensin. Monensin inhibits acidification of endosomes and lysosomes and thus blocks dissociation of the ligand from the receptor and consequently further cellular uptake of this ligand. In addition, monensin prevents the release of receptor-ligand containing vesicles from the microtubuli (29, 30) . Incubation of HSC with monensin under our experimental conditions did not affect the viability of HSC as assessed with trypan blue exclusion tests. Fig. 8B shows that total radioactivity incorporated in HSC declined to approximately 50% with monensin (p Ͻ 0.001), indicating internalization of pCVI-HSA via an endosomal and lysosomal pathway. Uptake of mannose 6-phosphate-modified albumin, known to be endocytosed by cells (31, 32) , was also inhibited by monensin, by 63%. 2 Despite uptake of the modified albumin by HSC was found, only minor degradation products (non-trichloroacetic acid precipitable radioactivity) were detected in the media following incubations for 2 h. To determine cellular degradation of pCVI-HSA, we incubated 125 I-pCVI-HSA and 125 I-HSA with slices prepared from fibrotic livers. As can be derived from Fig. 9 , incubation of these slices with pCVI-HSA resulted in an increased formation of degradation products in time, whereas native HSA was not degraded by these hepatic cells.
To confirm the data of the in vitro binding studies with radiolabeled proteins, primary cultures of activated HSC were incubated with unlabeled pCVI-HSA for immunohistochemical analysis. We could clearly demonstrate the binding of pCVI-HSA to activated HSC, while unmodified HSA showed no association with the cells. Furthermore, the binding of pCVI-HSA to HSC could be inhibited by the presence of excess collagen type VI, while a polyanion such as suramin did not prevent binding of pCVI-HSA to the HSC in vitro (Fig. 10) .
Finally, we studied the in vitro binding of 125 I-pCVI-HSA to different collagen types I, III, IV, and VI. These matrix proteins are abundantly present in fibrotic livers. As can be seen in Fig.  11 , pCVI-HSA displayed a higher binding to collagen S, a mixture of collagen type I (95%) and collagen type III (5%), as compared with 125 I-HSA. The binding to collagen was also found in experiments with purified forms of collagen. pCVI-HSA displayed a higher binding for collagen type VI and interstitial collagens type III and I than for type IV collagen. In all cases, significantly higher amounts of pCVI-HSA were associated with collagen proteins as compared with HSA (p Ͻ 0.01).
DISCUSSION
To increase the cell-specific uptake of antifibrotic drugs, we developed drug carriers to HSC. Receptors expressed on (activated) HSC may serve as targets for such carriers. Activated HSC avidly bind collagen type VI, which is an important matrix protein involved in the binding of cells to extracellular matrix proteins. Since the cyclic RGD-peptide, C*GRGDSPC*, specifically binds to mesenchymal cells via collagen type VI receptors (19) , it was used to design a specific carrier for HSC in fibrotic livers. A construct of approximately 10 cyclic peptides attached to human albumin was employed to study the liver selectivity of pCVI-HSA in normal rats and in rats with liver fibrosis and to study the cellular handling by HSC.
Quality assessment of the pCVI-HSA preparations led to the conclusion that the product was mostly monomeric. Attachment of cyclic peptides to the lysine groups of albumin might result in conformational changes of the albumin backbone due to electrostatic interactions between the carrier and the attached peptide moiety or the reaction conditions used for the coupling of cyclic peptides to HSA may cause a denaturation or refolding of the albumin molecule. This may lead to immunogenic responses or nonspecific removal by Kupffer cells or other macrophages in vivo (33) . The identical CD spectra of pCVI- HSA and HSA, however, indicated that the conformation of the albumin molecule was not affected by the introduction of the 10 C*GRGDSPC* groups to albumin.
In vivo experiments demonstrated that pCVI-HSA strongly accumulated in rat livers. Ten minutes after intravenous injection, about 75% (normal livers) and 62% (fibrotic livers) of the dose pCVI-HSA was distributed to the livers, whereas unmodified HSA completely remained in the blood. The majority of hepatic cells in BDL3 rats that bound pCVI-HSA were identified as HSC, whereas in normal rat livers pCVI-HSA was mainly distributed to endothelial cells. This binding to endothelial cells may be explained by the ability of endothelial cells to bind matrix molecules (34) , but also by the presence of other protein removal systems (35) . pCVI-HSA displayed only minor binding to Kupffer cells, the hepatic cell type involved in the removal of large molecular weight molecules and foreign particles (33) . Therefore, although the total distribution of pCVI-HSA to normal and fibrotic rat livers is almost identical, the intrahepatic distribution is completely different. This may be due to disease-induced changes in the sinusoidal endothelial cells or to the increased number of activated HSC in fibrotic livers in combination with increased numbers of collagen type VI receptors on these cells.
Immunohistochemical staining of fibrotic liver sections showed a distribution of pCVI-HSA to the non-parenchymal cells in zones II and III, but not to cells in the periportal areas where most ␣-smooth muscle actin-positive cells (activated HSC) reside. To study whether pCVI-HSA is able to bind to activated HSC, we performed binding studies with cultured rat HSC. These in vitro studies demonstrated that pCVI-HSA specifically bound to the activated HSC compared with minimal binding to quiescent HSC. These results could be confirmed by immunohistochemical studies demonstrating the preferential binding of pCVI-HSA to cultured activated HSC. Inhibition of the cellular binding of pCVI-HSA in the presence of collagen type VI but not in the presence of the polyanion suramin further indicated that the binding to these cells was specific. In addition, different types of purified collagens (I, III, VI, and IV) interfered with 125 I-pCVI-HSA binding to HSC (data not shown). There are several reasons for the discrepancy between the in vitro studies showing binding to activated HSC and the results obtained in vivo that demonstrate lack of binding in periportal areas where activated HSC reside. Since the accessibility of hepatic cells in the portal area may be hampered during fibrosis due to increased collagen deposition, pCVI-HSA may not have reached the portal areas in vivo as early as 10 min after intravenous injection. Also, a competition between the modified albumins and endogenous substrates, such as collagen type VI (14, 15) present at these particular sites in fibrotic livers, may occur in diseased livers. Therefore, the binding to these cells may be enhanced by prolonged exposure to the carrier. Accordingly, we showed in vitro that an increase in the incubation time to 24 h resulted in a 10-fold higher binding of pCVI-HSA to HSC than incubation for 2 h. Binding of pCVI-HSA to HSC in vivo in zones II and III may also indicate that HSC in these areas of the fibrotic livers express more collagen type VI receptors than those in zone I.
In addition to the activated HSC specificity of the carrier, any extrahepatic uptake of the carrier must be considered to anticipate possible side effects of drugs. However, organ distribution studies showed that the extrahepatic uptake of pCVI-HSA in fibrotic rats was low (less than 5% was present in spleen, kidneys, and other organs). Although the radioactive studies indicated distribution of pCVI-HSA to bone, muscles, and skin, immunohistochemical analysis of these organs could not confirm its cell associated presence in these tissues. The gradually increasing amounts of pCVI-HSA in skin and muscles in time probably represented redistribution of parts of 125 I-pCVI-HSA degraded in the liver. Therefore, although some extrahepatic uptake of pCVI-HSA was found, the major part of the intravenous injected pCVI-HSA distributed to the (fibrotic) livers. In vitro studies showed enhanced binding of pCVI-HSA to different types of collagen (I, III, IV, and VI) as compared with HSA. The immunohistochemically based organ distribution studies performed in vivo, however, did not show any association with the extracellular matrix. The significance of the matrix binding properties of the carrier has to be considered, but relative to the binding of pCVI-HSA to HSC it will only play a minor role in vivo.
In the present study, we showed that pCVI-HSA was internalized by HSC. This is in accordance with studies performed by Everts et al. (36) demonstrating uptake and degradation of collagen type VI in the lysosomes of fibroblasts. Cellular uptake of pCVI-HSA allows the delivery of antifibrotic drugs that interfere with intracellular processes. Among the drugs of interest are the inhibitors of collagen synthesis such as prolyl-4-hydroxylase inhibitors (37, 38) , activators of collagenase expression/activation, like pentoxifylline (39), or inhibitors of HSC activation (NFB inhibitors or histone deacetylase inhibitors (40 -42) ).
The modified albumin pCVI-HSA is not only endocytosed but also degraded by the liver cells. The latter was assessed in vitro (rat liver slices) as well as in vivo. The in vivo studies showed a decreased liver content of pCVI-HSA in time together with a recovery of degradation products (free 125 I) in the urine of these rats. In vitro studies confirmed the in vivo data: degradation products were released by slices incubated with pCVI-HSA. The biological degradation has implications for the drug targeting concept since accumulation of a compound within the cell will cause toxicity of the compound and moreover, release of active compounds within the cell will be limited if the carrier would not be degraded. If necessary, release characteristics of the drug could be improved by coupling of the drug to the carrier via, for instance, a spacer, which will cause release of drugs in the endosomes (43) .
pCVI-HSA may also have intrinsic activities, that is, a direct influence on the fibrotic process itself (44) . It is known that integrin-mediated cell attachment in general influences and regulates cell migration, growth, differentiation, and apoptosis of cells (10) . Collagen type VI potently regulates mesenchymal cell proliferation and activation in vitro (17, 18) . Like single chain collagen type VI, the peptide-modified albumin pCVI-HSA may interfere with processes of HSC activation by blocking cellular binding sites of native collagen type VI. RGDcontaining peptides were reported to interfere with liver fibrogenesis and other wound healing processes (45) (46) (47) .
Previously, we reported about the specific distribution of albumin modified with mannose 6-phosphate groups (M6P 28 -HSA) to HSC (9) . The selectivity of the distribution of this M6P 28 -HSA to HSC was similar to that of pCVI-HSA. The specificity of pCVI-HSA, however, may be further optimized by varying the amount of cyclic peptides or by variations in the amino acids flanking the RGD motif (10, 48, 49) . Whether neoglycoproteins or peptide-modified albumins represent the most optimal carrier remains to be established.
Targeting receptors by substituting albumin with (cyclic) peptide motifs is a new approach in the design of drug targeting preparations. Due to structural stabilization, cyclization of peptide motifs is associated with a higher affinity for the receptors compared with their linear analogues (18, 48, 50) . The design of carrier molecules described in this study may also be applicable for other receptors, such as cytokine or growth factor receptors (48, (51) (52) (53) . Studies on drug carriers to the platelet-derived growth factor receptor are in progress. The targeting to receptors that are up-regulated on the activated fibrogenic cells in pathological processes may also be applicable for targeting of therapeutic agents to other fibrogenic processes, such as atherosclerosis or glomerulosclerosis (54) .
Drug targeting also offers possibilities in more pathological or fundamental research areas. Targeting of pharmacological active agents to an individual cell type offers the advantage of selective elimination of one cell type or blockade of a single process within this cell type. After specific inhibition of a process, the implications for the development of a particular disease can be studied. In this way, drug targeting allows us to gain more insight in the molecular basis of diseases in vivo. As a consequence, drug targeting preparations may create new leads for novel therapeutic interventions.
In conclusion, we showed that HSA modified with cyclic peptides, that contain RGD sequences, represents a new type of carrier. pCVI-HSA is preferentially taken up by activated rat HSC. Application of this novel carrier may strongly increase the tissue selectivity and efficacy of antifibrotic drugs. Since the core amino acids (RGD) responsible for receptor binding are identical in rats and humans, pCVI-HSA may also be applied in cirrhotic patients.
